2022
Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How?
Rabiee A, Garcia‐Tsao G, Tapper EB. Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How? Clinical Liver Disease 2022, 19: 118-123. PMID: 35355838, PMCID: PMC8958249, DOI: 10.1002/cld.1182.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2016
Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis
Ripoll C, Augustin S, Reiberger T, Moreau R, Salerno F, Albillos A, Abraldes J, Garcia-Tsao G. Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis. 2016, 333-339. DOI: 10.1007/978-3-319-23018-4_33.Peer-Reviewed Original ResearchComplications of cirrhosisNon-bleeding complicationsNonselective beta blockersBeta blockersLower incidenceSecondary prophylaxisHepatic encephalopathyHepatocellular carcinomaBeneficial effectsLower dysfunction rateNon-hemodynamic effectsDysfunction rateVariceal bleedingCurrent therapiesCovered stentsHemodynamic responseBetter survivalComplicationsCirrhosisBlockersProphylaxisAscitesEarly TIPSIncidencePatients